Mark Baldry Sells 29,159 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) insider Mark Baldry sold 29,159 shares of the firm’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $13,121.55. Following the sale, the insider now directly owns 94,123 shares of the company’s stock, valued at approximately $42,355.35. The trade was a 23.65 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

X4 Pharmaceuticals Stock Up 3.0 %

Shares of XFOR opened at $0.49 on Tuesday. The firm has a market capitalization of $83.84 million, a price-to-earnings ratio of -5.46 and a beta of 0.14. X4 Pharmaceuticals, Inc. has a 52 week low of $0.26 and a 52 week high of $1.60. The company has a debt-to-equity ratio of 1.26, a quick ratio of 4.80 and a current ratio of 4.89. The business’s fifty day moving average price is $0.55 and its two-hundred day moving average price is $0.61.

Wall Street Analysts Forecast Growth

XFOR has been the subject of several research analyst reports. Stifel Nicolaus cut their price objective on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and set a $1.50 price target on shares of X4 Pharmaceuticals in a research report on Tuesday, January 14th.

Hedge Funds Weigh In On X4 Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Verition Fund Management LLC acquired a new position in X4 Pharmaceuticals during the 3rd quarter valued at about $30,000. SG Americas Securities LLC bought a new stake in shares of X4 Pharmaceuticals during the third quarter worth approximately $37,000. XTX Topco Ltd acquired a new position in X4 Pharmaceuticals in the second quarter valued at approximately $65,000. Rhumbline Advisers boosted its stake in X4 Pharmaceuticals by 14.6% in the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock valued at $109,000 after acquiring an additional 23,831 shares during the last quarter. Finally, Jane Street Group LLC raised its position in shares of X4 Pharmaceuticals by 103.4% during the 3rd quarter. Jane Street Group LLC now owns 248,447 shares of the company’s stock valued at $166,000 after acquiring an additional 126,296 shares during the last quarter. Institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.